ストックスクリーナーアプリを入手
55.75
0.52%
-0.29
アフターアワーズ：
55.75
前日終値:
$56.04
開ける：
$57.3
24時間の取引高:
1.68M
Relative Volume:
0.71
時価総額：
$8.53B
収益：
$700.35M
当期純損益:
$461.90M
株価収益率:
19.43
EPS:
2.8696
ネットキャッシュフロー:
$-14.19M
1週間 パフォーマンス:
+3.32%
1か月 パフォーマンス:
-0.14%
6か月 パフォーマンス:
+81.01%
1年 パフォーマンス:
+51.08%
1日の値動き範囲:
$55.60
$57.58
1週間の範囲:
$51.28
$57.58
52週間の値動き範囲:
$25.28
$59.30
Tg Therapeutics Inc Stock (TGTX) Company Profile
名前
Tg Therapeutics Inc
セクター
電話
(212) 554-4484
住所
2 GANSEVOORT STREET, 9TH FLOOR, NEW YORK, NY
Compare TGTX vs VRTX, REGN, ARGX, RVMD, ALNY
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TGTX
Tg Therapeutics Inc
|
55.75 | 8.58B | 700.35M | 461.90M | -14.19M | 2.8696 |
VRTX
Vertex Pharmaceuticals Inc
|
479.00 | 121.16B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
667.17 | 68.78B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
888.82 | 57.44B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
188.07 | 40.23B | 742.00K | -1.37B | -1.07B | -7.0731 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.40 | 36.28B | 4.29B | 577.22M | 641.34M | 4.2086 |
Tg Therapeutics Inc Stock (TGTX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-06 | 再開されました | H.C. Wainwright | Buy |
| 2025-07-10 | 再開されました | Goldman | Neutral |
| 2024-10-29 | 開始されました | TD Cowen | Buy |
| 2023-08-02 | アップグレード | Goldman | Sell → Neutral |
| 2023-06-26 | 再開されました | Jefferies | Buy |
| 2022-05-20 | 開始されました | BofA Securities | Underperform |
| 2022-02-23 | 繰り返されました | B. Riley Securities | Buy |
| 2021-11-15 | ダウングレード | Goldman | Neutral → Sell |
| 2021-04-20 | 開始されました | Goldman | Neutral |
| 2021-04-19 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-09-01 | 開始されました | JP Morgan | Overweight |
| 2020-08-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-06-05 | 開始されました | Evercore ISI | Outperform |
| 2020-01-17 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-11-27 | 再開されました | B. Riley FBR | Buy |
| 2019-02-06 | 再開されました | Jefferies | Buy |
| 2018-09-25 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2018-03-09 | 繰り返されました | B. Riley FBR, Inc. | Buy |
| 2017-12-01 | 再開されました | B. Riley FBR, Inc. | Buy |
| 2017-11-14 | 再開されました | H.C. Wainwright | Buy |
| 2017-04-25 | 開始されました | Jefferies | Buy |
| 2017-03-06 | 繰り返されました | FBR & Co. | Outperform |
| 2016-10-06 | 再開されました | Brean Capital | Buy |
| 2016-05-27 | 開始されました | SunTrust | Buy |
| 2015-12-01 | 開始されました | FBR Capital | Outperform |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-08-12 | 再開されました | H.C. Wainwright | Buy |
| 2015-06-19 | 繰り返されました | Brean Capital | Buy |
| 2014-12-11 | 繰り返されました | ROTH Capital | Buy |
| 2014-12-10 | 繰り返されました | ROTH Capital | Buy |
すべてを表示
Tg Therapeutics Inc (TGTX) 最新ニュース
TGTX Maintains Buy Rating -- Price Target Raised to $86.00 by B. Riley Securities - GuruFocus
META_TITLE_QUOTE - Yahoo Finance
TG Therapeutics (TGTX) to Report Q2 Results: Wall Street Expects Earnings Growth - Yahoo Finance
B. Riley Raises Price Target on TG Therapeutics to $86 From $55, Keeps Buy Rating - marketscreener.com
TG Therapeutics Inc (TGTX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
TG THERAPEUTICS INC : B. RILEY RAISES TARGET PRICE TO $86 FROM $55 - Bitget
TG Therapeutics, Inc. Revenue Breakdown – FWB:NKB2 - TradingView
TradingKey - TradingKey
TG Therapeutics Inc (TGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
TG Therapeutics Inc (TGTX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TG Therapeutics, Inc. Revenue Breakdown – LS:A1JXW7 - TradingView
TGTX|TG Therapeutics Inc|Price:56.040|Chg%:+0.540 - TradingKey
TGTX|TG Therapeutics Inc|Price:56.650| - TradingKey
TG Therapeutics, Inc. (TGTX) stock price, news, quote and history - Yahoo Finance UK
TG Therapeutics, Inc. (TGTX) Stock Price, News, Quote & History - Yahoo! Finance Canada
TG Therapeutics Inc (TGTX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
TGTX: TG Therapeutics Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
TG Therapeutics Inc (TGTX) Fundamental & Financial Data - Stocktwits
TG Therapeutics Holds Steady Near $54 Amid ConsolidationValue Area Low - dars.gov.et
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - Morningstar
(TGTX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Triangle's highest-paid public company CEO earned $25M in 2025. Here's how others stacked up. - The Business Journals
TG Therapeutics, Inc. (TGTX): Investor Outlook on a Biotech Powerhouse with 6.39% Upside Potential - DirectorsTalk Interviews
TG THERAPEUTICS INC : TD COWEN RAISES TARGET PRICE TO $75 FROM $50 - Bitget
TGTX Stock Rises On Wall Street Price Target Hike, New Schizophrenia Trial Launch - Stocktwits
ETFs Investing in TG Therapeutics, Inc. Stocks - TradingView
Law firm investigates TG Therapeutics officers for possible self-dealing harming shareholders - Pluang
Kuehn Law Encourages Investors of TG Therapeutics, Inc. to Contact Law Firm - GlobeNewswire Inc.
Did BRIUMVI’s Phase 2 Schizophrenia Trial Just Shift TG Therapeutics' (TGTX) Investment Narrative? - simplywall.st
TG THERAPEUTICS INC : JP MORGAN RAISES TARGET PRICE TO $65 FROM $46 - webull.com
Analysts Conflicted on These Healthcare Names: Biogen (BIIB) and TG Therapeutics (TGTX) - The Globe and Mail
TG Therapeutics (TGTX) Gets a Buy from H.C. Wainwright - The Globe and Mail
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $83 - Moomoo
H.C. Wainwright Maintains TG Therapeutics(TGTX.US) With Buy Rating, Raises Target Price to $77 - Moomoo
TG Therapeutics (TGTX) Gains as Its Key Drug Exceeded Expectations - Yahoo Finance
TGTX Maintained by HC Wainwright & Co. -- Price Target Raised to $77 - GuruFocus
TG Therapeutics, Inc. (TGTX) Stock Analysis: A Healthcare Standout with Robust Revenue Growth - DirectorsTalk Interviews
Is TG Therapeutics (TGTX) Fully Valued Following Its New Schizophrenia Trial Launch? - Sahm
TG Therapeutics Initiates Phase 2 Trial of Briumvi, Expanding Pipeline PotentialGuidance Upgrade Report - DonanımHaber
TGTX Stock Hits Fresh 52-Week High – Here’s Why Retail Is Bullish Despite Q1 Earnings Miss - Stocktwits
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Insider Monkey
TG Therapeutics (TGTX) Stock May Still Be Cheap Despite New Trial News - Yahoo Finance
2 Fast-Growing Pharmaceutical Stocks to Buy Now - The Motley Fool
Can TG Therapeutics' (TGTX) Schizophrenia Trial Meaningfully Redefine BRIUMVI’s Role Beyond Multiple Sclerosis? - Yahoo Finance
Is TG Therapeutics (TGTX) Fully Valued Following Its Schizophrenia Trial Update? - Yahoo Finance
Bank of America Securities Keeps Their Sell Rating on TG Therapeutics (TGTX) - The Globe and Mail
5 Best Performing American Stocks in June 2026 - Insider Monkey
Moderna, TG Therapeutics, Agios Pharmaceuticals Q2 Results May Face Increased Scrutiny, BofA Says - Moomoo
TGTX Maintained by B of A Securities -- Price Target Raised to $20 - GuruFocus
TG Therapeutics stock hits 52-week high at 57.4 USD By Investing.com - Investing.com Nigeria
TG Therapeutics stock hits 52-week high at 57.4 USD - Investing.com
Tg Therapeutics Inc (TGTX) 財務データ
収益
当期純利益
現金流量
EPS
1.97%
0.83%
大文字化:
|
ボリューム (24 時間):